Recently, there was a news report stating that “clinical research on prenatal testing (NIPT) is being expanded to cover ‘all chromosomes.’”
For those who are trying to conceive through sperm donation (or are considering it), this is not just someone else’s problem. As pregnancy becomes a real possibility, the question of “how to proceed with testing” becomes a practical decision that must be made; moreover, because NIPT is so convenient—requiring only a blood draw—it’s an area where misinformation can spread quickly, often leading to growing anxiety.
In this article, I’ll break down the key points of this news story, explain what whole-chromosome NIPT (non-invasive prenatal testing for chromosomal abnormalities) actually is, and clarify how it relates to trying to conceive with a sperm donor—all from as practical a perspective as possible.
Clinical trials to examine "all chromosomes" are expected to begin at 11 facilities
According to media reports, 11 medical institutions nationwide are expected to begin a clinical study as early as February on NIPT—a test that screens for fetal chromosomal abnormalities using the mother’s blood—to examine “all chromosomes.” The study will involve approximately 2,000 pregnant women and is expected to begin sequentially at facilities as they become ready, continuing through the end of March 2030.
The background to this issue is the current framework, under which testing is (primarily) limited to the presence or absence of three specific types of chromosomal abnormalities—with a positive result confirmed through amniocentesis or similar procedures—and the problem that tests claiming to detect abnormalities other than these three are becoming widespread at “unaccredited facilities,” causing confusion among pregnant women due to insufficient verification of accuracy and inadequate counseling systems.
In short, it is natural to view this move not simply as an “expansion of the scope of testing,” but rather as a shift toward restructuring a broad range of NIPT services, including validation and system infrastructure.
What Is “Whole-Chromosome NIPT”? A Comprehensive Approach to Chromosomes 1–22 and the Sex Chromosomes
When researching NIPT, you’ll come across a long list of numbers like “Chromosome 1” and “Chromosome 21.” Roughly speaking, chromosomes are divided into autosomes (1 through 22) and sex chromosomes (X and Y), and they are numbered in order of length.
NIPT, which is now widely known, primarily screens for “numerical abnormalities (trisomies)” of chromosomes 21, 18, and 13. On the other hand, some medical institutions advertise “all chromosomes” and describe a screening framework that more broadly screens for aneuploidy of chromosomes 1 through 22 plus the sex chromosomes.
The key point here is the realization that “looking at everything” does not equate to “omniscience.” While a broader perspective allows you to gather more information, it also tends to increase the number of areas where interpreting the results becomes difficult. I believe that’s precisely why this news story mentions “conducting clinical research to verify accuracy”—because that is the main challenge.
To begin with, NIPT is not a “definitive diagnosis.”
A key point to understand about NIPT is that it is a screening test (non-diagnostic test). Guidelines from organizations such as the Japan Society of Obstetrics and Gynecology clearly state that NIPT is a “non-diagnostic test” that uses the ratio of fetal DNA fragments in maternal blood to indicate a high likelihood of numerical abnormalities in chromosomes 13, 18, and 21, and that chromosomal analysis via amniocentesis or other methods is required for a definitive diagnosis.
The basic principles are the same overseas as well. ACOG states that cfDNA (NIPT) is a screening test with high sensitivity and specificity for common aneuploidies, but that it is not equivalent to a diagnostic test.
The SMFM also recommends diagnostic confirmation via CVS or amniocentesis before making important decisions based on abnormal results.
The issue highlighted in the news—that “pregnant women are confused by an inadequate counseling system”—can be rephrased as a problem that tends to arise when testing proceeds without first explaining the “difference between screening and diagnosis.”
While amniocentesis provides a more "definitive" diagnosis, it is an invasive procedure that carries risks.
Amniocentesis is the most common definitive diagnostic test.According to information provided by Jikei University School of Medicine, amniocentesis is a “definitive diagnostic test” performed around the 15th to 16th week of pregnancy. While it can diagnose fetal chromosomal and genetic disorders, it carries a risk of complications such as rupture of membranes, bleeding, and infection; the risk of miscarriage or stillbirth is reported to be approximately 1 in 300 to 1 in 500 (0.2–0.3%).
This isn’t a matter of right or wrong—it’s simply “reality.” Since NIPT only requires a blood draw, the psychological barrier is lower; as a result, some people are surprised by the weight of the “next decision” (whether or not to undergo confirmatory testing) when they receive a positive result. If you take a moment to imagine the possible paths you might take after receiving the results before undergoing the test, you’ll be less likely to feel overwhelmed than necessary.
When you expand the scope to include all chromosomes, some people feel more reassured, while others feel more uncertain.
It’s natural to want to minimize anxiety as much as possible. In particular, since trying to conceive—including through sperm donation—is a “path you’ve chosen for yourself,” I get the impression that many people want to move forward with this process only after they’re fully on board.
However, as the test is expanded to cover all chromosomes, there is an increased likelihood of encountering abnormalities with low frequencies or results that are difficult to interpret. Since NIPT is not a diagnostic test, false positives and false negatives cannot be completely eliminated; therefore, the fundamental principle remains that when a result is “positive” or “high-risk,” a recommendation for diagnostic testing or a decision regarding further steps will be necessary.
As explained in Hiro Clinic’s overview, the comprehensive chromosome aneuploidy test provides a comprehensive screening for aneuploidy across chromosomes 1 through 22 and all sex chromosomes.
On the other hand, since this explanation comes from the provider of the test, it is realistic for those undergoing the test to keep in mind that “the more information you have, the more decisions you have to make.” The fact that this study is proceeding—including verification of accuracy—suggests that society is currently in the process of reevaluating this very issue.
How Are Sperm Donation and NIPT Related to Trying to Conceive?
Since this is a point that’s often misunderstood, I’ll explain it carefully.
NIPT (within the generally accepted scope) is a test that primarily screens for fetal chromosomal abnormalities (such as trisomies 13, 18, and 21).
On the other hand, when it comes to sperm donation, the focus is often on “information about the parents”—such as the donor’s health history, family history, and, in some cases, carrier screening. While these topics may seem similar, the scope of the tests is slightly different.
However, there are situations where NIPT becomes a practical consideration even when trying to conceive through sperm donation. As pregnancy becomes more likely, the option of prenatal testing comes into view. The less you’ve shared this with those around you, the fewer people you’ll have to turn to for support in coping with the results, making it easy to feel isolated with only the information to go on. That is precisely why it’s valuable to understand the nature of the test—that it is a screening test and that a positive result may require confirmatory testing—in advance.
Summary: The spread of whole-chromosome NIPT is both “good news” and “an issue that needs to be addressed.”
According to recent reports, a clinical study to expand the scope of NIPT to cover all chromosomes is expected to begin at 11 facilities nationwide. The study is scheduled to run through the end of March 2030 and will involve approximately 2,000 pregnant women.
Reports indicate that this initiative is in response to concerns that tests other than the three approved types are becoming widespread at uncertified facilities, causing confusion among pregnant women due to insufficient verification of accuracy and inadequate counseling systems.
While whole-chromosome NIPT takes a broader approach by examining autosomes 1 through 22 (plus the sex chromosomes), since NIPT is a screening test, it is essential to consider the results in the context of their interpretation and the subsequent decisions (such as diagnostic testing).
While amniocentesis has the advantage of providing results that are closer to a definitive diagnosis, it is also true that it is an invasive procedure and carries certain risks.
For those trying to conceive through sperm donation, it’s not just a matter of “how much peace of mind you can have,” but also “how much information you can handle” that’s an important consideration. Information can be a tool, but too much of it can be exhausting. That’s why I think the most realistic approach is not to corner yourself into a binary choice of “accept or reject,” but rather to understand the nature of the tests and choose the option that feels right to you.
(*This article is intended to provide general information only and is not a substitute for medical judgment. Please consult a healthcare provider regarding your testing options.)